RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase-III study Meeting Abstract
| Authors: | Motzer, R. J.; Escudier, B.; Oudard, S.; Porta, C.; Hutson, T. E.; Bracarda, S.; Hollaender, N.; Urbanowitz, G.; Kay, A.; Ravaud, A. |
| Abstract Title: | RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter phase-III study |
| Meeting Title: | 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 26 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2008 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2008-05-20 |
| Start Page: | 256s |
| Language: | English |
| ACCESSION: | WOS:000208457401925 |
| DOI: | 10.1200/jco.2008.26.15_suppl.lba5026 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA5026 -- Full text available in Journal of Clinical Oncology 26(18 Suppl.): 1009s and online -- Source: Wos |
